西咪替丁对接受血液透析患者的治疗效果。
Therapeutic effect of cimetidine in patients undergoing haemodialysis.
作者信息
Jones R H, Lewin M R, Parsons V
出版信息
Br Med J. 1979 Mar 10;1(6164):650-2. doi: 10.1136/bmj.1.6164.650.
Blood concentrations of cimetidine were measured and the therapeutic effect of the drug assessed patients undergoing maintenance haemodialysis. Thirteen patients were given a single oral 200-mg dose of cimetidine a mean of 2.7 hours before the start of dialysis. Dialysing for 6--12-6 m2 hours led to a mean fall of 71% in blood cimetidine concentration during haemodialysis. Nine patients with various upper gastrointestinal lesions diagnosed endoscopically were treated for up to six weeks with a reduced cimetidine dose of 200 mg 12-hourly; two patients received two courses of treatment. Repeat endoscopy after treatment disclosed satisfactory healing, and the drug did not accumulate. This lower dose regimen is recommended for patients receiving dialysis who develop upper gastrointestinal lesions for which a histamine H2-receptor antagonist is indicated.
对接受维持性血液透析的患者测定了西咪替丁的血药浓度，并评估了该药物的治疗效果。13名患者在透析开始前平均2.7小时口服了200毫克单剂量的西咪替丁。透析6 - 12 - 6平方米小时导致血液透析期间西咪替丁血药浓度平均下降71%。9名经内镜诊断为各种上消化道病变的患者，以每12小时200毫克的减少剂量西咪替丁治疗长达六周；两名患者接受了两个疗程的治疗。治疗后重复内镜检查显示愈合良好，且药物未蓄积。对于接受透析且发生需要使用组胺H2受体拮抗剂治疗的上消化道病变的患者，推荐使用这种较低剂量的治疗方案。
Zotero 插件